Immunome Analysts Cut Their Forecasts After Q3 Results
Stifel Maintains Hold on Immunome, Lowers Price Target to $23
Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
Immunome Files Prospectis Offering For Offering 4.425M Common Shares
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know
Immunome Stock Gets EMA Review For Desmoid Tumor Drug
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026
William Blair Initiates Coverage On Immunome with Outperform Rating
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.